Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Not Yet Opened 01-12 16:00:00 EST

4.13

+0.02

+0.49%

盘后4.05

-0.08-1.94%

19:24 EST

High4.19	Low3.95	Vol617.51K
Open4.07	D1 Closing4.11	Amplitude5.96%
Mkt Cap248.47M	Tradable Cap200.23M	Total Shares60.16M
T/O2.52M	T/O Rate1.27%	Tradable Shares48.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":4.13,"timestamp":1768251600000,"preClose":4.11,"halted":0,"volume":617505,"hourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4.13,"latestTime":"19:24 EST","volume":12339,"amount":50915.927,"timestamp":1768263857858},"delay":0,"floatShares":48481525,"shares":60162773,"eps":-0.720975,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"01-12 16:00:00 EST","open":4.07,"high":4.19,"low":3.945,"amount":2524436.3931150003,"amplitude":0.059611,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.720975,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":4.11,"preHourTrading":{"tag":"盘前","latestPrice":4.11,"preClose":4.11,"latestTime":"09:28 EST","volume":583,"amount":2388.2383371,"timestamp":1768228127747},"postHourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4.13,"latestTime":"19:24 EST","volume":12339,"amount":50915.927,"timestamp":1768263857858},"volumeRatio":0.700408,"impliedVol":2.2614,"impliedVolPercentile":0.8884},"requestUrl":"/m/hq/s/ALDX/wiki","defaultTab":"wiki","newsList":[{"id":"2600068849","title":"Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2600068849","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600068849?lang=en_us&edition=fundamental","pubTime":"2026-01-02 19:26","pubTimestamp":1767353199,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics  said in a regulatory filing Wednesday that Chief Development Officer Stephen G. Machatha notified the company of his intent to resign to pursue other opportunities, effective around March 31.Machatha's resignation did not stem from any disagreement with Aldeyra, the company said in its 8-K filing with the US Securities and Exchange Commission.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2600584704","title":"Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2600584704","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600584704?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:07","pubTimestamp":1767218868,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL1kgQgQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2591861189","title":"Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2591861189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591861189?lang=en_us&edition=fundamental","pubTime":"2025-12-16 19:28","pubTimestamp":1765884480,"startTime":"0","endTime":"0","summary":"Shares of Aldeyra Therapeutics were sharply lower in premarket trading Tuesday after the biotechnology company said the U.S. Food and Drug Administration's review of its proposed reproxalap treatment for dry-eye disease has been extended by three months.Aldeyra late Monday said that the FDA has extended its target action date for a decision on reproxalap to March 16, 2026, after the Lexington, Mass., company last week submitted a report on a dry-eye-disease field trial of reproxalap, which the agency deemed a major amendment to the application seeking approval of the drug.Aldeyra shares, which closed Monday at $3.99, were recently down 15% at $3.39 in premarket trading.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2591607416","title":"Aldeyra Therapeutics Shares Drop 14.3% Premarket After Pdufa Extension of Its Drug Candidate for Dry Eye Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2591607416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591607416?lang=en_us&edition=fundamental","pubTime":"2025-12-16 17:14","pubTimestamp":1765876470,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL4N3XM0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2591451673","title":"BRIEF-Aldeyra Therapeutics Announces PDUFA Extension Of The New Drug Application Of Reproxalap For The Treatment Of Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2591451673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591451673?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:31","pubTimestamp":1765845072,"startTime":"0","endTime":"0","summary":"BRIEF-Aldeyra Therapeutics Announces PDUFA Extension Of The New Drug Application Of Reproxalap For The Treatment Of Dry Eye DiseaseDec 15 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THERAPEUTI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8PLPT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2591736166","title":"Aldeyra Therapeutics Announces Pdufa Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2591736166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591736166?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:30","pubTimestamp":1765845000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8PLPT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2591673126","title":"Aldeyra Therapeutics Inc - Extended Pdufa Target Action Date Is March 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591673126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591673126?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:30","pubTimestamp":1765845000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8PLPT9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2583985405","title":"Aldeyra Therapeutics Showcases Broad Immunology Pipeline Targeting Immune-Mediated Diseases in New R&D Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2583985405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583985405?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:07","pubTimestamp":1763039264,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL6j513P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2583567666","title":"BRIEF-Aldeyra Therapeutics Announces Expansion of RASP Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567666?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:29","pubTimestamp":1763036958,"startTime":"0","endTime":"0","summary":"BRIEF-Aldeyra Therapeutics Announces Expansion of RASP PlatformNov 13 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THERAPEUTICS ANNOUNCES EXPANSION OF RASP PLATFORM TO INCLUDE CENTRAL NERVOUS S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUABHFVZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2583628075","title":"Aldeyra Therapeutics Reports Positive Preclinical Results for ADX-248 in Neurological Disease Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2583628075","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583628075?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035254,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. announced new preclinical research results during a recently held research and development webcast. The company revealed that its next-generation RASP modulator, ADX-248, demonstrated promising outcomes in preclinical models of Parkinson's disease and amyotrophic lateral sclerosis. Results showed improvements in grip strength, balance, and central nervous system biomarkers, supporting the potential of ADX-248 as a treatment for neuroinflammatory diseases. The webcast also included updates on the manufacturing of reproxalap, with Aldeyra reporting that recent FDA inspections of its manufacturing facilities were completed with no further action required.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4BZCzV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2583644125","title":"Aldeyra Therapeutics Announces Expansion of Rasp Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2583644125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583644125?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUABHFVZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2582365107","title":"Aldeyra Therapeutics to Join Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365107","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365107?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:01","pubTimestamp":1762862507,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on November 20, 2025. President and CEO Todd C. Brady will discuss the company's activities with Clara Dong, Vice President at Jefferies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL32yZqk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2582822428","title":"Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2582822428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582822428?lang=en_us&edition=fundamental","pubTime":"2025-11-10 18:37","pubTimestamp":1762771020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 05:37 ET (10:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0},{"id":"2580226184","title":"Aldeyra Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580226184","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580226184?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:55","pubTimestamp":1762206905,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF2DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2579997780","title":"High Growth Tech Stocks In The US Market With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2579997780","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579997780?lang=en_us&edition=fundamental","pubTime":"2025-10-29 01:08","pubTimestamp":1761671293,"startTime":"0","endTime":"0","summary":"Amid a backdrop of record highs in major stock indexes and anticipation surrounding the Federal Reserve's interest rate decisions, the U.S. market is witnessing a dynamic phase where tech stocks are capturing significant attention. In this environment, identifying high growth potential often involves looking at companies that can leverage technological advancements like AI to drive innovation and expansion.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aldx/aldeyra-therapeutics/news/high-growth-tech-stocks-in-the-us-market-with-promising-pote-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aldx/aldeyra-therapeutics/news/high-growth-tech-stocks-in-the-us-market-with-promising-pote-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CAN","BK7096","BK4023","BK4170","BK7502","BK4600","BK4595","ALDX","BK4139","CAN.AU","BK4526","AVPT","BK7508"],"gpt_icon":1},{"id":"2578095195","title":"Aldeyra ADX-629 achieves statistically significant improvement in liver function","url":"https://stock-news.laohu8.com/highlight/detail?id=2578095195","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578095195?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:06","pubTimestamp":1761653169,"startTime":"0","endTime":"0","summary":"Aldeyra (ALDX) announced achievement of statistically significant improvement in liver function in patients treated with ADX-629, an investigationa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aldeyra-adx-629-achieves-statistically-significant-improvement-in-liver-function-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aldeyra-adx-629-achieves-statistically-significant-improvement-in-liver-function-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX","ADX"],"gpt_icon":0},{"id":"2578195868","title":"Aldeyra Therapeutics Reports Positive Phase 2 Results for ADX-629 in Alcohol-Associated Hepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2578195868","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578195868?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:03","pubTimestamp":1761649418,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. announced positive results from a Phase 2 clinical trial evaluating ADX-629, an investigational RASP modulator, in patients with mild to moderate alcohol-associated hepatitis. The single-arm, multicenter study involved oral administration of ADX-629 for one month in four patients. Statistically significant improvements were observed in markers of hepatic function and inflammation, including the Model for End-Stage Liver Disease  score , triglyceride levels , and C-Reactive Protein levels . No serious adverse events were reported, and no adverse events were considered related to ADX-629. The company indicated that these positive results mark the culmination of clinical proof-of-concept for ADX-629, and that further details will be shared in the future. Aldeyra also announced a strategic shift in its pipeline to focus on next-generation RASP modulators, specifically ADX-248 and ADX-246, for the treatment of immune-mediated diseases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDLPSv2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2578930024","title":"Aldeyra Therapeutics Inc - Adx-629 Shows Significant Improvement in Liver Function","url":"https://stock-news.laohu8.com/highlight/detail?id=2578930024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578930024?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:01","pubTimestamp":1761649260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA2PCYTP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2578307909","title":"Aldeyra Therapeutics Announces Positive Results From Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses Rasp Product Candidate Pipeline on Next-Generation Molecules","url":"https://stock-news.laohu8.com/highlight/detail?id=2578307909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578307909?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:01","pubTimestamp":1761649260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA2PCYTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2578300449","title":"Aldeyra Therapeutics Inc - Cash Runway Extended Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2578300449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578300449?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:01","pubTimestamp":1761649260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA2PCYTP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.0903},{"period":"3month","weight":-0.2266},{"period":"6month","weight":-0.1996},{"period":"1year","weight":-0.164},{"period":"ytd","weight":-0.2027}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.051736},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.002242},{"month":3,"riseRate":0.454545,"avgChangeRate":0.009696},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.007872},{"month":5,"riseRate":0.363636,"avgChangeRate":0.012368},{"month":6,"riseRate":0.333333,"avgChangeRate":0.032526},{"month":7,"riseRate":0.583333,"avgChangeRate":0.052566},{"month":8,"riseRate":0.5,"avgChangeRate":0.050447},{"month":9,"riseRate":0.5,"avgChangeRate":0.169785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.091942},{"month":11,"riseRate":0.666667,"avgChangeRate":0.079554},{"month":12,"riseRate":0.416667,"avgChangeRate":-0.031913}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction